467
edits
No edit summary |
No edit summary |
||
Line 153: | Line 153: | ||
===Treatments to reduce cardiovascular risk=== | ===Treatments to reduce cardiovascular risk=== | ||
{| class="wikitable" border="0" cellpadding="0" cellspacing="0" width="600px" | |||
|- | |||
!colspan="3"|Treatment to reduce cardiovascular risk <cite>34</cite> | |||
|- | |||
|colspan="3"|'''Lifestyle and comprehensive management''' | |||
|- | |||
!Recommendation | |||
!Class<sup>a</sup> | |||
!Level<sup>b</sup> | |||
|- | |||
|Structured patient education improves metabolic and blood pressure control | |||
!I | |||
!A | |||
|- | |||
|Non-pharmacological life style therapy improves metabolic control | |||
!I | |||
!A | |||
|- | |||
|Self-monitoring improves glycaemic control | |||
!I | |||
!A | |||
|- | |||
|Near normoglycaemic control (HbA1c 6.5%<sup>c</sup> | |||
reduces microvascular complications | |||
reduces macrovascular complications | |||
!I | |||
!A | |||
|- | |||
|Intensified insulin therapy in type 1 diabetes reduces morbidity and mortality | |||
!I | |||
!A | |||
|- | |||
|Early escalation of therapy towards predefined treatment targets improves a composite of morbidity and mortality in type 2 diabetes | |||
!IIa | |||
!B | |||
|- | |||
|Early initiation of insulin should be considered in patients with type 2 diabetes failing glucose target | |||
!IIb | |||
!C | |||
|- | |||
|Metformin is recommended as first line drug in overweight type 2 diabetes | |||
!IIa | |||
!B | |||
|- | |||
|bgcolor="#CCCCFF" colspan="3"|'''<sup>a</sup>Class of recommendation.''' | |||
'''<sup>b</sup>Level of evidence.''' | |||
'''<sup>c</sup>Diabetes Control and Complication Trial-standardized.''' | |||
|} | |||
To reduce the risk of cardiovascular disease, the followings are needed to be considered: | To reduce the risk of cardiovascular disease, the followings are needed to be considered: | ||
edits